ArticleChest2023
Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension.
Article in Chest, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.Journal of the American Heart Association · 2024Pooled it
- Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Center Study?Anatolian journal of cardiology · 2026Article
- Association of Immunoglobulin E With Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.Pulmonary circulation · 2026Article
- Transthoracic echocardiography of left ventricular underfilling improves risk stratification in pulmonary arterial hypertension.Scientific reports · 2025Article
- Refining Risk Prediction in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2025Article
- Advanced Echocardiographic Assessment Predicts 1-Year Mortality in Critically Ill Patients With Pulmonary Arterial Hypertension.JACC. Advances · 2025Article
- Interpretable Machine Learning Model for Pulmonary Hypertension Risk Prediction: Retrospective Cohort Study.JMIR medical informatics · 2025Article
- The role of imaging in risk assessment for pulmonary arterial hypertension.Current opinion in cardiology · 2025Review
- Pulmonary arterial hypertension treatment. A new era.International journal of cardiology. Congenital heart disease · 2025Review
- Unilateral Absence of Pulmonary Artery Complicated With Severe Pulmonary Hypertension: Favorable Response to Parenteral Therapy.JACC. Case reports · 2025Article
- Comparison of the prognostic value of right atrial echocardiographic parameters in pulmonary arterial hypertension.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025Article
- Article
- Refining Prognostication and Therapeutic Guidance Through Advances in Right Heart Imaging Approaches.The Canadian journal of cardiology · 2025Review
- Article
- An Unsupervised Approach to Derive Right Ventricular Pressure-Volume Loop Phenotypes in Pulmonary Hypertension.Pulmonary circulation · 2025Article
- Echocardiographic Grading of Right Ventricular Afterload in Left Heart Disease: Relation to Right Ventricular Function, Pulsatile and Resistant Load, and Outcome.Pulmonary circulation · 2025Article
- Echocardiography of the right heart in pulmonary arterial hypertension: insights from the ULTRA RIGHT VALUE study.European heart journal. Imaging methods and practice · 2025Article
- Risk factors and predictive model for pulmonary arterial hypertension in adult idiopathic-inflammatory-myopathy patients: A cross-sectional study.Clinics (Sao Paulo, Brazil) · 2025Article
- Pathophysiology of the right ventricle and its pulmonary vascular interaction.The European respiratory journal · 2024Review
- Risk stratification and treatment goals in pulmonary arterial hypertension.The European respiratory journal · 2024Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiparametric risk assessment tools determine mortality risk in patients with pulmonary arterial hypertension (PAH) by combining invasive and noninvasive variables so management strategies can be tailored to individuals. RESEARCH QUESTION: Can a risk score based on common echocardiographic parameters risk-stratify patients with PAH? STUDY DESIGN AND
methodsA Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) echocardiographic risk score (REVEAL-ECHO) was derived using retrospective echocardiographic data from 2,400 adult patients with PAH enrolled in the REVEAL registry database. A stepwise Cox regression model identified echocardiographic parameters significantly predictive of survival. Values were assigned to each selected parameter based on survival at 12 months' follow-up (Kaplan-Meier estimates). The REVEAL-ECHO risk score was the sum of individual values. Patients were categorized as having low, intermediate, or high risk based on Kaplan-Meier-predicted 12-month survival.
resultsThe risk score included four echocardiographic parameters-right ventricular (RV) chamber enlargement, reduced RV systolic function, tricuspid regurgitation severity, and pericardial effusion-and accounted for PAH etiology. Higher REVEAL-ECHO risk scores signaled lower probability of 12-month survival. Statistically significant separation of mortality risk was observed among the risk strata: intermediate vs low (hazard ratio [HR], 1.43; 95% CI, 1.17-1.75; P = .0004) and high vs low (HR, 2.60; 95% CI, 2.19-3.10; P < .0001). Augmentation of the REVEAL Lite 2 risk calculator with REVEAL-ECHO risk scores achieved separation of REVEAL Lite 2 into four risk groups and identified a subgroup of patients with a low REVEAL Lite 2 risk score who were at higher risk (intermediate-low risk) and a subgroup of patients with an intermediate REVEAL Lite 2 risk score who also were at higher risk (intermediate-high risk).
interpretationA REVEAL-ECHO risk score, derived using four echocardiographic parameters, may discriminate risk further when used as an adjunct to current risk assessment scores. Further validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.